Neurotoxin that blocks neuromuscular transmission via irreversible inhibition of nicotinic ACh receptors (nAChRs). Prevents opening of nicotinic receptor-associated ion channels and is selective for α7 receptors over α3β4 receptors (IC50 values are 1.6 nM

FITC-α-Bungarotoxin is the FITC-labeled form of α-Bungarotoxin, which acts as a competitive antagonist at nicotinic acetylcholine receptors (nAChRs) [1].

κ-Bungarotoxin (κ-Bgt) is a selective and potent antagonist of α3β2 neuronal nicotinic acetylcholine receptors, exhibiting slow reversibility and an IC50 of 2.30 nM [1].

αC-Conotoxin PrXA is a neurotoxic paralytic peptide acting as a competitive antagonist of the nicotinic acetylcholine receptor (nAChR), exhibiting inhibitory constants (IC50) of 1.8 nM for the adult α1β1εδ subtype and 3.0 nM for the fetal α1β1γδ subtype. The compound vies with α-bungarotoxin for binding sites at the α/δ and α/γ interfaces of neuromuscular nAChRs, demonstrating high selectivity[1].

Biotin-α-Bungarotoxin is a biotinylated form of α-Bungarotoxin, which acts as a competitive antagonist at nicotinic acetylcholine receptors (nAChRs) [1].